In today’s briefing:
- Ant Group: Shareholder Restructuring Announced and the Lack of IPO Plan Are Negatives Surprise
- China Internet Weekly (9Jan2023): Ant Group, Alibaba, Tencent, ByteDance, China Literature
- Youlife International Pre-IPO Tearsheet
- Morning Views Asia: Sands China, SJM Holdings, Yanlord Land
- Perfectly Imperfect
- Ant Group Completed Equity Structure Adjustment
- Shanghai Junshi Bioscience (1877.HK/688180.CH)- Junshi Has Changed Its Story from Tumor to COVID-19?
Ant Group: Shareholder Restructuring Announced and the Lack of IPO Plan Are Negatives Surprise
- The announced restructuring of Ant Group holding companies will block founder Jack Ma from achieving majority voting on the board following the implementation of the holdcos adjustment
- The majority of board directors will be “independent” post the holdco restructuring and they are likely to drive a more social policy focused agenda, as the 2021 sustainability report suggests
- We see these developments, and especially the lack of IPO plan, to be negative for non-government aligned Ant Group shareholders, such as the international private equity groups and especially Alibaba
China Internet Weekly (9Jan2023): Ant Group, Alibaba, Tencent, ByteDance, China Literature
- A state-owned company invested in Ant Group, which boosted Alibaba’s stock price.
- Tencent obtained five new game licenses in December, three of which are imported games.
- China Literature’s daily active users increased by 80% in 2022 and reached the historical high.
Youlife International Pre-IPO Tearsheet
- Youlife International Holdings (1759732D CH) is looking to raise at least US$100m in its upcoming HK IPO. The deal will be run by Macquarie and CCB International.
- Youlife International is a blue-collar lifetime service platform in China. It assists blue-collar talent with upskilling and lifetime career development.
- According to CIC, Youlife ranked first among all blue-collar lifetime service platforms in China in terms of revenue generated from blue-collar lifetime services in 2021.
Morning Views Asia: Sands China, SJM Holdings, Yanlord Land
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
Perfectly Imperfect
- Artificial Intelligence (AI) and Deep Learning Applications are all the rage, primarily thanks to the likes of OpenAI’s ChatGPT being used for text and Dall-E being used to generate digital images.
- ChatGPT’s popularity has soared, reaching a user base of 1 million users in 5 days, and OpenAI itself is benefiting from the surge in users, now valued at $29 Billion.
- Investors are already looking for the next wave of AI products that can make a big splash and potentially disrupt legacy industries.
Ant Group Completed Equity Structure Adjustment
- CBIRC approved the capital replenishment plan of RMB10.5bn of Ant CFC on Dec 30, 2022
- Under the regulatory guidance, Ant Group needs to complete a multifaceted rectification plan
- After the fund raising, Ant Group’s next step is to obtain FHC license and credit bureau license
Shanghai Junshi Bioscience (1877.HK/688180.CH)- Junshi Has Changed Its Story from Tumor to COVID-19?
- Junshi once generated sales and profits in scale, but lost money again. Its story suddenly changed from cancer drugs to COVID-19. We have lost sight of its development direction.
- Junshi’s commercialization history has lost its reference value for confirming the outlook. The calculation of peak sales doesn’t make much sense, because they cannot help Junshi turn losses into profits.
- The current market value still has too much “bubble”, and COVID-19 drug is a major “interference” to the valuation. We analyzed our thoughts on future valuation by excluding COVID-19 projects.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars